Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)

Condition:   Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions:   Drug: TPF2;   Other: Radiotherapy with carboplatin
Sponsor:   Centre Antoine Lacassagne
Not yet recruiting - verified April 2017

http://ift.tt/2pexL5k